Press releases

LinKinVax has the trust of world-class partners and investors.

Our last Press releases

January 19, 2023

LinKinVax and Gustave Roussy collaborate to conduct a Phase I/IIa HPV.DCVax clinical trial for the treatment of patients with human papillomavirus (HPV) associated oropharyngeal cancer

January 10, 2023

LinKinvax just completed a new round of financing, initiated in 2022

October 13, 2022

Accelerating the production of more effective prophylactic or therapeutic vaccines and adapting them to emerging or rapidly mutating pathogens is a major public health challenge.

May 20, 2022

LinKinVax puts together a highly experienced team from the world of biopharmaceuticals to lead the clinical development and upscaling of its vaccine platform

May 4, 2022

LinKinVax appoints Dr Jiong Ma as independent board member 

LinKinVax's Logo
March 15, 2022

LinKinVax announces a collaboration with GTP Bioways for the development and production of its second-generation vaccine against SARS-CoV-2

LinKinVax's Logo
February 10, 2022

LINKINVAX raises €4.350 million in funding

To accelerate the developpement of its innovative vaccine platform
LinKinVax's Logo
February 3, 2022

LINKINVAX and INSERM TRANSFERT enter into an exclusive woldwild licensing agreement

Covering use of an innovative vaccine platform.
LinKinVax's Logo
June 21, 2021

Biotech start-up LinKinvax is created to accelerate the development, clinical trial and market access of a unique and innovative vaccine platform 

Biotech start-up LinKinvax is created to accelerate the development, clinical trial and market access of a unique and innovative vaccine platform

SUBSCRIBE TO UPDATE !